Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 255-261

  Kuiper, Justine L ^a   Hendriks, Lizza E ^b   van der Wekken, Anthonie J ^c   de Langen, Adrianus J ^a,d   Bahce, Idris ^a,d   Thunnissen, Erik ^a   Heideman, Daniëlle A M ^a   Berk, Yvonne ^e   Buijs, Ed J M ^a   Speel, Ernst Jan M ^b   Krouwels, Frans H ^f   Smit, Hans J M ^g   Groen, Harry J M ^c   Dingemans, Anne Marie C ^b   Smit, Egbert F ^a,h  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f Department of Orthopaedic Surgery   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

EGFR; Leptomeningeal metastasis; NSCLC; TKI

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; CYTOPATHOLOGY; DEMOGRAPHY; DRUG MEGADOSE; DRUG SUBSTITUTION; DUTCHMAN; FEMALE; FOLLOW UP; HUMAN; LEPTOMENINGEAL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINX DISORDER; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938740585     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.05.023     Document Type: Article

References (37)

1. Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006, 5(5):443-452.
2. Gwak H.S., Joo J., Kim S., Yoo H., Shin S.H., Han J.Y., et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013, 8(5):599-605.
3. Morris P.G., Reiner A.S., Szenberg O.R., Clarke J.L., Panageas K.S., Perez H.R., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012, 7(2):382-385.
4. Omuro A.M., Kris M.G., Miller V.A., Franceschi E., Shah N., Milton D.T., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103(11):2344-2348.
5. Togashi Y., Masago K., Masuda S., Mizuno T., Fukudo M., Ikemi Y., et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012, 70(3):399-405.
6. Du C., Hong R., Shi Y., Yu X., Wang J. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol 2013, 115(2):285-291.
7. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13(12):1364-1369.
8. Lee E., Keam B., Kim D.W., Kim T.M., Lee S.H., Chung D.H., et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013, 8(8):1069-1074.
9. Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M., et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013, 8(2):185-191.
10. Lee Y., Han J.Y., Kim H.T., Yun T., Lee G.K., Kim H.Y., et al. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol 2013, 115(1):95-101.
11. Park J.H., Kim Y.J., Lee J.O., Lee K.W., Kim J.H., Bang S.M., et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012, 76(3):387-392.
12. Riess J.W., Nagpal S., Iv M., Zeineh M., Gubens M.A., Ramchandran K., et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer 2014, 15(3):202-206.
13. Shingyoji M., Kageyama H., Sakaida T., Nakajima T., Matsui Y., Itakura M., et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 2011, 6(7):1215-1220.
14. Yi H.G., Kim H.J., Kim Y.J., Han S.W., Oh D.Y., Lee S.H., et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009, 65(1):80-84.
15. Umemura S., Tsubouchi K., Yoshioka H., Hotta K., Takigawa N., Fujiwara K., et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012, 77(1):134-139.
16. Katayama T., Shimizu J., Suda K., Onozato R., Fukui T., Ito S., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4(11):1415-1419.
17. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp; 2015.
18. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
19. Eichler A.F., Kahle K.T., Wang D.L., Joshi V.A., Willers H., Engelman J.A., et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010, 12(11):1193-1199.
20. Masuda T., Hattori N., Hamada A., Iwamoto H., Ohshimo S., Kanehara M., et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011, 67(6):1465-1469.
21. Clarke J.L., Pao W., Wu N., Miller V.A., Lassman A.B. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99(2):283-286.
22. Kuiper J.L., Heideman D.A., Thunnissen E., van Wijk A.W., Postmus P.E., Smit E.F. High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. Eur J Cancer 2014, 50(7):1399-1401.
23. Milton D.T., Azzoli C.G., Heelan R.T., Venkatraman E., Gomez J.E., Kris M.G., et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 2006, 107(5):1034-1041.
24. Kuiper J.L., Smit E.F. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well. Lung Cancer 2013, 80(1):102-105.
25. Jackman D., Mach S., Heng J.C., Rabin M.S., Barbie D.A., Gandhi L., et al. Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2013, 31. (suppl; abstr 8116).
26. Hoffknecht P., Tufman A., Wehler T., Pelzer T., Wiewrodt R., Schutz M., et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2015, 10(1):156-163.
27. Janne P.A., Ramalingam S.S., Chih-Hsin Yang J., Kim D.W., Kim S.W., Planchard D., et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32(5s). (suppl; abstr 8009).
28. Sequist L.V., Soria J.C., Gadgeel S.M., Wakelee H.A., Camidge D.R., Varga A., et al. First in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014, 32(5s). (suppl; abstr 8010).
29. Chamberlain M.C., Eaton K. Is there a role for whole brain radiotherapy in the treatment of leptomeningeal metastases?. J Thorac Oncol 2012, 7(7):1204-1205.
30. Chamberlain M.C. Leptomeningeal metastasis. Curr Opin Oncol 2010, 22(6):627-635.
31. Chamberlain M., Soffietti R., Raizer J., Ruda R., Brandsma D., Boogerd W., et al. Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014, 16(9):1176-1185.
32. Niibe Y., Chang J.Y. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012, 2012:261096.
33. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37(4):745-751.
34. Hendriks L.E., Troost E.G., Steward A., Bootsma G.P., De J.K., van den Borne B.E., et al. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: impact of a new Dutch guideline on brain metastases. Acta Oncol 2014, 53(7):945-951.
35. Chamberlain M.C. Leptomeningeal metastasis. Semin Neurol 2010, 30(3):236-244.
36. Glass J.P., Melamed M., Chernik N.L., Posner J.B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29(10):1369-1375.
37. Wasserstrom W.R., Glass J.P., Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49(4):759-772.